Calidi Biotherapeutics, Inc.
$1.10
-$0.17 (-13.39%)
$1.10Day Range$1.28
Key Statistics
Market Cap
$2.84M
Shares Outstanding
2.6M
Primary Exchange
XASE
Currency
USD
Type
CS
IPO Date
Sep 13, 2023
Round Lot
100
Locale
US
Trading Data
Day Open
$1.28
Day High
$1.28
Day Low
$1.10
Volume
32.7K
VWAP
$1.16
Prev Close
$1.27
Transactions
--
Acc. Volume
--
About Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283629 employees4475 EXECUTIVE DRIVE, SAN DIEGO, CA, 92121858-794-9600IPO Sep 13, 2023US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001855485
- Composite FIGI
- BBG012QFCL84
- Share Class FIGI
- BBG012QFCL93
- Ticker Root
- CLDI
- SIC Code
- 2836
About Calidi Biotherapeutics, Inc. (CLDI) Stock
Calidi Biotherapeutics, Inc. (CLDI) closed the 2026-09-18 session at $1.10, down 13.39% versus the previous close (-0.17). The stock opened at $1.28 and traded between $1.10 and $1.28 during that session. Session trading volume was 33K shares. The volume-weighted average price (VWAP) is $1.16.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
Calidi Biotherapeutics, Inc. has a market capitalization of $2.8 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. CLDI is listed on the XASE exchange. The company employs approximately 29 people. Calidi Biotherapeutics, Inc. is headquartered in SAN DIEGO, CA. The recorded listing date is 2023-09-13.
On this page you can find market CLDI stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.